Download PDF
Drug Res (Stuttg) 2020; 70(08): 376-384
DOI: 10.1055/a-1201-2700
Original Article

Combination of Lorcaserin and GLP-1/glucagon Coagonist Improves Metabolic Dysfunction in Diet Induced-obese Mice

Vishal Patel
1   Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India
,
Amit Joharapurkar
1   Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India
,
Samadhan Kshirsagar
1   Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India
,
Maulik Patel
1   Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India
,
Hardikkumar Savsani
1   Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India
,
Rajesh Bahekar
1   Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India
,
Mukul Jain
1   Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background Obesity and diabetes are major metabolic disorders that progress to severe morbidity and mortality. Neuroendocrine mechanisms controlling energy balance indicate that combination therapies are needed to sustain weight loss. Lorcaserin was one of the approved therapies for the treatment of obesity, which is recently withdrawn because a safety clinical trial, shows an increased occurrence of cancer. Coagonist of glucagon-like-peptide-1 (GLP-1) and glucagon receptors is a novel investigational therapy demonstrated to have both anti-obesity and anti-diabetic effect. Here, we investigated the effect of combination of lorcaserin and a GLP-1 and glucagon receptors coagonist in diet-induced obese (DIO) mice model.

Methods The diet-induced obese C57BL/6J mice were used to assess acute and chronic effect of lorcaserin, coagonist of GLP-1and glucagon receptors and their combination on food intake, body weight, and biochemical parameters.

Results In acute study, combination of lorcaserin and coagonist causes synergistic reductions in food intake and body weight. Repeated treatment of combination of lorcaserin and coagonist showed enhanced body weight loss over time, which is due to reduction in fat mass (subcutaneous, retroperitoneal, mesenteric and epididymal fat pad) compared to individual therapy. Also, suppression of locomotor activity seen with lorcaserin was not evident in combination with coagonist. No additive effect was observed in glucose tolerance (intraperitoneal glucose tolerance test or insulin tolerance test), serum lipids, hepatic lipids, and energy expenditure in combination group.

Conclusion These data suggest that combination of lorcaserin and coagonist could be a better combination to induce body weight loss.

Key words

drug research - metabolic pharmacology - pharmacology - GLP-1 - glucagon - lorcaserin - combination - diabetes - obesity


Publication History

Received: 22 May 2020

Accepted: 15 June 2020

Article published online:
09 July 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Mandviwala T, Khalid U, Deswal A. Obesity and Cardiovascular Disease: A Risk Factor or a Risk Marker?. Curr Atheroscler Rep 2016; 18: 21
    CrossrefPubMedGoogle Scholar
  • 2 Engin A. The definition and prevalence of obesity and metabolic syndrome. In: Engina Atilla, Eds. Advances in Experimental Medicine and Biology. Springer; 2017: 1-17
    Google Scholar
  • 3 Coulter AA, Rebello CJ, Greenway FL. Centrally acting agents for obesity: Past, present, and future. Drugs. 2018; 78: 1113-1132
    PubMedGoogle Scholar
  • 4 Narayanaswami V, Dwoskin LP. Obesity: Current and potential pharmacotherapeutics and targets. Pharmacol Ther 2017; 170: 116-147
    CrossrefPubMedGoogle Scholar
  • 5 Pilitsi E, Farr OM, Polyzos SA. et al. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism 2019; 92: 170-192
    CrossrefPubMedGoogle Scholar
  • 6 Kumar R, Ryan D. Lorcaserin Departs, Leaving More Questions than Answers. Obesity 2020; DOI: 10.1002/oby.22789. Published online ahead of print, 2020 Apr 22
    CrossrefPubMedGoogle Scholar
  • 7 Shukla AP, Kumar RB, Aronne LJ. Lorcaserin Hcl for the treatment of obesity. Expert Opin Pharmacother 2015; 16: 2531-2538
    CrossrefPubMedGoogle Scholar
  • 8 Greenway FL, Shanahan W, Fain R. et al. Safety and tolerability review of lorcaserin in clinical trials. Clin Obes 2016; 6: 285-295
    CrossrefPubMedGoogle Scholar
  • 9 O’Neil PM, Birkenfeld AL, McGowan B. et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018; 392: 637-649
    CrossrefPubMedGoogle Scholar
  • 10 Mosenzon O, Blicher TM, Rosenlund S. et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): A placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol 2019; 7: 515-527
    CrossrefPubMedGoogle Scholar
  • 11 Patel V, Joharapurkar A, Kshirsagar S. et al. Therapeutic potential of coagonists of glucagon and GLP-1. Cardiovasc Hematol Agents Med Chem 2015; 12: 126-133
    CrossrefPubMedGoogle Scholar
  • 12 Pocai A, Carrington PE, Adams JR. et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 2009; 58: 2258-2266
    CrossrefPubMedGoogle Scholar
  • 13 Day JW, Ottaway N, Patterson JT. et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009; 5: 749-757
    CrossrefPubMedGoogle Scholar
  • 14 Zhu Q, Wang J, Bian X. et al. Novel synthesis of antiobesity drug lorcaserin hydrochloride. Org Process Res Dev 2015; 19: 1263-1267
    CrossrefPubMedGoogle Scholar
  • 15 Patel V, Joharapurkar A, Kshirsagar S. et al. Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition. Chem Biol Interact 2018; 282
    PubMedGoogle Scholar
  • 16 Thomsen WJ, Grottick AJ, Menzaghi F. et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: In vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008; 325: 577-587
    CrossrefPubMedGoogle Scholar
  • 17 Patel VJ, Joharapurkar AA, Kshirsagar SG. et al. Activation of GLP-1 and glucagon receptors regulates bile homeostasis independent of thyroid hormone. Curr Mol Pharmacol 2019; 12: 139-146
    CrossrefPubMedGoogle Scholar
  • 18 Stokes A, Preston SH. The contribution of rising adiposity to the increasing prevalence of diabetes in the United States. Prev Med (Baltim) 2017; 101: 91-95
    CrossrefPubMedGoogle Scholar
  • 19 Twig G, Afek A, Derazne E. et al. Diabetes risk among overweight and obese metabolically healthy young adults. Diabetes Care 2014; 37: 2989-2995
    CrossrefPubMedGoogle Scholar
  • 20 Grandone A, Di Sessa A, Umano GR. et al. New treatment modalities for obesity. Best Pract Res Clin Endocrinol Metab 2018; 32: 535-549
    CrossrefPubMedGoogle Scholar
  • 21 Srivastava G, Apovian C. Future pharmacotherapy for obesity: New anti-obesity drugs on the horizon. Curr Obes Rep 2018; 7: 147-161
    CrossrefPubMedGoogle Scholar
  • 22 Bohula EA, Wiviott SD, McGuire DK. et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med 2018; 379: 1107-1117
    CrossrefPubMedGoogle Scholar
  • 23 O’Neil PM, Smith SR, Weissman NJ. et al. Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study. Obesity 2012; 20: 1426-1436
    CrossrefPubMedGoogle Scholar
  • 24 Martin CK, Redman LM, Zhang J. et al. Lorcaserin, A 5-HT 2C receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab 2011; 96: 837-845
    CrossrefPubMedGoogle Scholar
  • 25 Chouchani ET, Kazak L, Spiegelman BM. New advances in adaptive thermogenesis: UCP1 and Beyond. Cell Metab 2019; 29: 27-37
    CrossrefPubMedGoogle Scholar
  • 26 Morrison SF, Madden CJ, Tupone D. Central neural regulation of brown adipose tissue thermogenesis and energy expenditure. Cell Metab 2014; 19: 741-756
    CrossrefPubMedGoogle Scholar
  • 27 Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: Controlling food intake and body weight. J Clin Invest 2014; 124: 4223-4226
    CrossrefPubMedGoogle Scholar
  • 28 Adams JM, Pei H, Sandoval DA. et al. Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons. Diabetes 2018; 67: 1538-1548
    CrossrefPubMedGoogle Scholar
  • 29 Burmeister MA, Ayala JE, Smouse H. et al. The hypothalamic glucagon-like peptide 1 receptor is sufficient but not necessary for the regulation of energy balance and glucose homeostasis in mice. Diabetes 2017; 66: 372-384
    CrossrefPubMedGoogle Scholar
  • 30 Abraham MA, Lam TKT. Glucagon action in the brain. Diabetologia 2016; 59: 1367-1371
    CrossrefPubMedGoogle Scholar
  • 31 Parker JA, McCullough KA, Field BCT. et al. Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int J Obes 2013; 37: 1391-1398
    CrossrefPubMedGoogle Scholar
  • 32 Patel VJ, Joharapurkar AA, Shah GB. et al. Effect of GLP-1 based therapies on diabetic dyslipidemia. Curr Diabetes Rev 2014; 10: 238-250
    CrossrefPubMedGoogle Scholar
  • 33 Pocai A. Unraveling oxyntomodulin, GLP1’s enigmatic brother. J Endocrinol 2012; 215: 335-346
    CrossrefPubMedGoogle Scholar
  • 34 Patel V, Joharapurkar A, Dhanesha N. et al. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice. Can J Physiol Pharmacol 2013; 91: 1009-1015
    CrossrefPubMedGoogle Scholar
  • 35 Day JW, Gelfanov V, Smiley D. et al. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers 2012; 98: 443-450
    CrossrefPubMedGoogle Scholar
  • 36 Burke LK, Ogunnowo-Bada E, Georgescu T. et al. Lorcaserin improves glycemic control via a melanocortin neurocircuit. Mol Metab 2017; 6: 1092-1102
    CrossrefPubMedGoogle Scholar
  • 37 Levin ED, Johnson JE, Slade S. et al. a 5HT2C agonist, decreases nicotine self-administration in female rats. J Pharmacol Exp Ther 2011; 338: 890-896
    CrossrefPubMedGoogle Scholar
  • 38 Ambery P, Parker VE, Stumvoll M. et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: A randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet 2018; 391: 2607-2618
    CrossrefPubMedGoogle Scholar
  • 39 Tillner J, Posch MG, Wagner F. et al. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diabetes, Obes Metab 2019; 21: 120-128
    CrossrefPubMedGoogle Scholar
  • 40 Nuffer WA, Trujillo JM. Liraglutide: A new option for the treatment of obesity. Pharmacotherapy 2015; 35: 926-934
    CrossrefPubMedGoogle Scholar
  • 41 Tan TM, Field BCT, McCullough KA. et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 2013; 62: 1131-1138
    CrossrefPubMedGoogle Scholar
  • 42 Scott R, Minnion J, Tan T. et al. Oxyntomodulin analogue increases energy expenditure via the glucagon receptor. Peptides 2018; 104: 70-77
    CrossrefPubMedGoogle Scholar
  • 43 Patel V, Joharapurkar A, Kshirsagar S. et al. Balanced coagonist of GLP-1 and glucagon receptors corrects dyslipidemia by improving FGF21 sensitivity in hamster model. Drug Res (Stuttg) 2017; 67: 730-736
    Article in Thieme ConnectPubMedGoogle Scholar